Investor Centre

Overview

Cann Group is a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and approved export markets. Cann has established research, cultivation and GMP manufacturing facilities in Bundoora, in northern Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group’s leading position in plant genetics, breeding, extraction, analysis and production techniques supports its objective to supply high quality, safe medicinal cannabis for a range of diseases and medical conditions. Incorporated in the Company's brand portfolio is its proprietary Satipharm delivery system for cannabinoids. Botanitech is a brand created by Cann and boasts a diverse, affordable and high-quality product range.

Cann Group Limited

Name

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

30 January 2015

Doug Rathbone AM Jenni Pilcher
Peter Kopanidis

The Company's Annual General Meeting will be held on Friday, 28th November 2025.

Please refer to the Annual General Meeting page of this website for further information on the 2025 AGM.